文献速递中枢神经肿瘤放疗放疗物理与技术

新诊断胶质母细胞瘤患者接受调强放疗为基础放化疗后放射性淋巴细胞减少的列线图:一项多中心研究

Nomogram for radiation-induced lymphopenia in patients receiving intensity-modulated radiotherapy based-chemoradiation therapy for newly diagnosed glioblastoma: A multi-institutional study.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-05-22

本回顾性多中心研究纳入2016至2021年两家医院接受调强放疗为基础同步放化疗的348例胶质母细胞瘤患者,21.0%发生严重淋巴细胞减少,且与较差总生存相关;基于性别、同步放化疗前绝对淋巴细胞计数和脑平均剂量构建的列线图预测准确性尚可(AUC 0.723)。

要点

  • 348例接受调强放疗为基础同步放化疗的胶质母细胞瘤患者中21.0%发生严重淋巴细胞减少。
  • 严重淋巴细胞减少与胶质母细胞瘤患者较差总生存结局相关。
  • 列线图纳入性别、同步放化疗前绝对淋巴细胞计数和脑平均剂量,AUC为0.723。

核心结论

  • 本研究提供了首个用于预测接受调强放疗为基础同步放化疗的胶质母细胞瘤患者严重淋巴细胞减少的列线图,预测准确性可接受。
  • 研究结果强调需要优化剂量和放疗计划以降低严重淋巴细胞减少风险。
  • 进一步外部验证对于在临床实践中采用该列线图至关重要。

研究设计与样本

  • 本回顾性研究回顾了2016年至2021年在两家大型医院接受调强放疗为基础同步放化疗的348例患者的数据。
  • 经多因素回归分析后开发列线图并进行内部验证以预测严重淋巴细胞减少风险。

主要发现

  • 治疗疗程期间21.0%的患者发生严重淋巴细胞减少。
  • 严重淋巴细胞减少与胶质母细胞瘤患者较差的总生存结局相关。
  • 新开发的列线图纳入性别、同步放化疗前绝对淋巴细胞计数和脑平均剂量,表现出尚可的预测准确性(AUC 0.723)。

关键数值与推荐

  • 列线图预测严重淋巴细胞减少的AUC为0.723。
  • 严重淋巴细胞减少发生率为21.0%(348例接受调强放疗为基础同步放化疗的患者)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出进一步外部验证对于在临床实践中采用该列线图至关重要。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Severe lymphopenia (SLP) has emerged as a significant prognostic factor in glioblastoma. Intensity-modulated radiation therapy (IMRT)-based radiation therapy (RT) is suggested to minimize the risk of SLP. This study aimed to evaluate SLP incidence based on multi-institutional database in patients with GBM treated with IMRT and develop a predictive nomogram. PATIENTS AND METHODS: This retrospective study reviewed data from 348 patients treated with IMRT-based concurrent chemoradiation therapy (CCRT) at two major hospitals from 2016 to 2021. After multivariate regression analysis, a nomogram was developed and internally validated to predict SLP risk. RESULTS: During treatment course, 21.0% of patients developed SLP and SLP was associated with poor overall survival outcomes in patients with GBM. A newly developed nomogram, incorporating gender, pre-CCRT absolute lymphocyte count, and brain mean dose, demonstrated fair predictive accuracy (AUC 0.723). CONCLUSIONS: This study provides the first nomogram for predicting SLP in patients with GBM treated with IMRT-based CCRT, with acceptable predictive accuracy. The findings underscore the need for dose optimization and radiation planning to minimize SLP risk. Further external validation is crucial for adopting this nomogram in clinical practice.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kim N, Lee J, Shin H, et al. Nomogram for radiation-induced lymphopenia in patients receiving intensity-modulated radiotherapy based-chemoradiation therapy for newly diagnosed glioblastoma: A multi-institutional study. Clin Transl Radiat Oncol. 2024. PMID: 38884005. doi:10.1016/j.ctro.2024.100799

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。